# Fjarde AP-fonden

> Fjarde AP-fonden is a VC fund in Stockholm backing Biotechnology and Real Estate. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 9
- Last investment: Dec 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/fj-rde-ap-fonden
- Website: http://www.ap4.se

Fjarde AP-fonden is a VC fund in Stockholm focused on Biotechnology and Real Estate. Fourth AP Fund is an investment management company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 33% |
| Real Estate | 2 | 22% |
| Pharmaceutical | 2 | 22% |
| Retail | 1 | 11% |
| Biopharma | 1 | 11% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 4 | 44% |
| Private Equity | 1 | 11% |
| Venture - Series Unknown | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Swedish Logistic Property | Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities. | $85.3M | Post-IPO Equity | Dec 03, 2025 |  |
| Vicore Pharma | Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $48M | Post-IPO Equity | Nov 13, 2025 |  |
| Stendorren Fastigheter | Stendorren Fastigheter is a company involved in the real estate industry. It develops, owns, operates, and maintains industrial, logistical, and warehouse facilities. The business offers adequate and suitable space on fair lease terms through its tenant. | $47.7M | Post-IPO Equity | Oct 23, 2024 |  |
| ITAB Shop Concept | ITAB Shop Concept sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The company offers custom-made fitting concepts, innovative solutions for checkout arena and professional lighting systems. | $85.1M | Post-IPO Equity | Sep 25, 2024 |  |
| Swedish Logistic Property | Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities. | $107.1M | Post-IPO Equity | Sep 04, 2024 |  |
| SmartCella | SmartCella is an innovative biotechnology and medtech company. Sweden. SmartCella’s therapeutic mission is to develop treatments for patients running out of options. The company has three main business units, Procella Therapeutics, Smartwise and SvedMed Solutions. | $54.2M | Private Equity | Jul 08, 2024 |  |
| Swedish Logistic Property | Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities. | $53.1M | Post-IPO Equity | Nov 29, 2023 |  |
| Vicore Pharma | Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $46.2M | Post-IPO Equity | Jun 09, 2023 |  |
| Cinclus Pharma | Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $24.1M | Venture - Series Unknown | May 20, 2022 |  |

9 of 9 investments shown.

## Co-investors
- Handelsbanken Fonder — VC Fund, 4 deals together
- [SEB (Skandinaviska Enskilda Banken)](https://shizune.co/investors/profile/seb) — VC Fund, 4 deals together
- [Länsförsäkringar](https://shizune.co/investors/profile/lnsfrskringar-skne) — VC Fund, 3 deals together
- [Clearance Capital](https://shizune.co/investors/profile/clearance-capital) — VC Fund, 2 deals together
- Danske Invest — VC Fund, 2 deals together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Fjarde AP-fonden invest in?

Fjarde AP-fonden invests primarily in Biotechnology, Real Estate and Pharmaceutical startups, most often at Post-IPO Equity and Private Equity stage. Most of the 9 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fjarde AP-fonden last invest?

The most recent investment recorded for Fjarde AP-fonden closed in Dec 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co